News
Language
Live Cam
Contact
Imprint
Ulm
English
en
Deutsch
de
Français
fr
News
Language
Live Cam
Contact
Imprint
English
en
Deutsch
de
Français
fr
EKM WS18 Introduction to Clinical Medicine
GTE Historical development of medicine
Medicine
Button
Robert Koch Institute
Red List
Pub Med
Dolosys
Cardiology
Clinical Oncology
JAN
28
Anbenitamab is a new second-line option in G/GEJ adenocarcinoma
By:
Diana Romero
on
JAN
28
Nature Reviews Clinical Oncology, Published online: 28 January 2026; doi:10.1038/s41571-026-01124-3Anbenitamab is a new second-line option in G/GEJ adenocarcinoma
Read more >>
JAN
23
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
By:
Liora Schultz
on
JAN
23
Nature Reviews Clinical Oncology, Published online: 23 January 2026; doi:10.1038/s41571-025-01115-wThis Review outlines the fundamental role of chimeric antigen receptor (CAR) T cell therapy for children, adolescents and young adults (CAYAs) with relapsed and/or refractory B cell acute lymphoblastic leukaemia, emphasizing the crucial need to further exploit CAR T cells and other immunotherapies to improve survival with broadened access across disease states. Opportunities and challenges for expanding CAR T cell therapy to other haematological and non-haematological malignancies in CAYAs are also discussed.
Read more >>
JAN
22
Diagnosis, risk stratification and management of smouldering multiple myeloma
By:
Saurabh Zanwar
on
JAN
22
Nature Reviews Clinical Oncology, Published online: 22 January 2026; doi:10.1038/s41571-026-01119-0Increased understanding of the biology of smouldering multiple myeloma (SMM) is being leveraged to improve the management of this clinically heterogeneous precursor of MM. This Review describes the current diagnostic work-up, risk stratification and management of SMM, highlighting early intervention approaches for high-risk SMM that might provide the best opportunity to convert MM into a curative disease and discussing persistent challenges in this field.
Read more >>
JAN
19
Author Correction: Advances in the management of localized bladder cancers
By:
Marie-Pier St-Laurent
on
JAN
19
Nature Reviews Clinical Oncology, Published online: 19 January 2026; doi:10.1038/s41571-026-01121-6Author Correction: Advances in the management of localized bladder cancers
Read more >>
JAN
15
MicroRNAs in oncology: a translational perspective in the era of AI
By:
Ancuta Jurj
on
JAN
15
Nature Reviews Clinical Oncology, Published online: 15 January 2026; doi:10.1038/s41571-025-01114-xDespite well-established roles of microRNAs (miRNAs) as tumour suppressors or oncogenes, miRNA-based diagnostics, prognostic tools and treatments have yet to be incorporated into routine oncology practice. In this Review, the authors discuss innovative approaches to address challenges in the clinical translation of miRNA-based diagnostics and treatments by integrating fundamental miRNA biology, multiomics and artificial intelligence-driven analyses.
Read more >>
JAN
07
A guide to cancer screening
By:
Stephen W. Duffy
on
JAN
07
Nature Reviews Clinical Oncology, Published online: 07 January 2026; doi:10.1038/s41571-025-01112-zCancer screening aims to identify either pre-malignant conditions or earlier-stage disease in non-symptomatic individuals. The authors of this Review recapitulate the general principles of cancer screening, discussing the current screening practices for several cancer types as well as advances in cancer detection that might hold promise for screening an increasing number of cancers in the future.
Read more >>
JAN
06
Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL
By:
Diana Romero
on
JAN
06
Nature Reviews Clinical Oncology, Published online: 06 January 2026; doi:10.1038/s41571-025-01118-7Base-edited CAR7 T cells are safe and efficacious in R/R T-ALL
Read more >>
JAN
06
Discovery of predictive biomarkers for cancer therapy through computational approaches
By:
Xin Wang
on
JAN
06
Nature Reviews Clinical Oncology, Published online: 06 January 2026; doi:10.1038/s41571-025-01109-8Treatment selection based on the presence of one or more specific biomarkers has the potential to optimize treatment outcomes; nonetheless, most patients lack a specific biomarker that is predictive of benefit from one or more targeted treatment approaches. In this Review, the authors describe the potential of computational analysis approaches to enable the discovery of more complex predictive biomarkers based on comprehensive analysis of large clinical and preclinical datasets and thus address this unmet need.
Read more >>
Weitere Beiträge
Endocrinology
JAN
16
GPR110 as a regulator of MASH
By:
Claire Greenhill
on
JAN
16
Nature Reviews Endocrinology, Published online: 16 January 2026; doi:10.1038/s41574-026-01231-2GPR110 as a regulator of MASH
Read more >>
JAN
15
Blood-based obesity biomarkers and their relevance for disease risk
By:
Tobias Pischon
on
JAN
15
Nature Reviews Endocrinology, Published online: 15 January 2026; doi:10.1038/s41574-025-01229-2Obesity is associated with changes in levels of many blood-based factors, such as cytokines and adipokines. This Review explores the utility of such factors as biomarkers for quantifying and predicting obesity-associated disease risk, including the identification of causal relationships.
Read more >>
JAN
09
Endocrine regulation of the hepatic fasting response: cues, cooperation and consequences
By:
Dana Goldberg
on
JAN
09
Nature Reviews Endocrinology, Published online: 09 January 2026; doi:10.1038/s41574-025-01228-3During fasting, the liver produces fuel under the control of several hormonal and metabolic cues. In this Review, the authors outline the effects of the cues (glucagon, glucocorticoids, growth hormone, adrenaline, free fatty acids, asprosin and GP73) that are known to directly signal to hepatocytes under fasting conditions.
Read more >>
JAN
08
The public health burden of diabetes mellitus and thyroid disease: twin epidemics
By:
Salman Razvi
on
JAN
08
Nature Reviews Endocrinology, Published online: 08 January 2026; doi:10.1038/s41574-025-01226-5This Review explores the link between diabetes mellitus and thyroid disease from an epidemiological and mechanistic perspective, and discusses the public health implications of this link and provides recommendations for clinical management and public health policy.
Read more >>
JAN
07
Tailoring interventions to close gaps in diabetes mellitus care
By:
Alicia Diaz-Thomas
on
JAN
07
Nature Reviews Endocrinology, Published online: 07 January 2026; doi:10.1038/s41574-025-01217-6This Review outlines the inequities that exist in the diagnosis, management and outcomes for minoritized people with diabetes mellitus. The authors also discuss how these inequities can be addressed to improve the care of people with diabetes mellitus globally.
Read more >>
JAN
06
Models of hyperglycaemia in diabetes mellitus and its complications
By:
Ryan Yi Hang Loo
on
JAN
06
Nature Reviews Endocrinology, Published online: 06 January 2026; doi:10.1038/s41574-025-01220-xMany different models are used in research into diabetes mellitus, and each has strengths and limitations. In this Review, the authors explain several in vivo and in vitro models of hyperglycaemia and discuss how future models might be improved to better replicate physiological conditions in people with diabetes mellitus.
Read more >>
JAN
05
ZMIZ1 supports endometrial oestrogen and progesterone signalling
By:
Senegal Carty
on
JAN
05
Nature Reviews Endocrinology, Published online: 05 January 2026; doi:10.1038/s41574-025-01230-9ZMIZ1 supports endometrial oestrogen and progesterone signalling
Read more >>
JAN
05
The autonomic nervous system in the regulation of glucose and lipid metabolism
By:
Sabrina Wangler
on
JAN
05
Nature Reviews Endocrinology, Published online: 05 January 2026; doi:10.1038/s41574-025-01221-wChronic disturbances in autonomic regulation are increasingly recognized as contributors to metabolic diseases such as obesity and type 2 diabetes mellitus. In this Review, Wangler and colleagues discuss bidirectional communication between the autonomic nervous system and peripheral tissues in the coordination of glucose and lipid metabolism as well as emerging therapies targeting autonomic pathways that could improve metabolic health.
Read more >>
Weitere Beiträge
GI and Hepatology
JAN
26
Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models
By:
Jack Leslie
on
JAN
26
Nature Reviews Gastroenterology & Hepatology, Published online: 26 January 2026; doi:10.1038/s41575-025-01162-9Preclinical models are essential to study disease pathogenesis and test novel treatments. Here, a broad overview of metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models is provided, detailing main features, advances and limitations of in vitro and in vivo models, and how they translate to human disease.
Read more >>
JAN
22
Dietary guidelines for gastrointestinal disorders: key to optimizing practice but more work needed
By:
Eirini Dimidi
on
JAN
22
Nature Reviews Gastroenterology & Hepatology, Published online: 22 January 2026; doi:10.1038/s41575-025-01171-8Nutrition and dietary guidelines in gastrointestinal disorders vary in scope, rigour and recommendations, contributing to variations in practice. This Comment identifies nutrition and dietary guidelines for gastrointestinal disorders, namely chronic constipation, irritable bowel syndrome and inflammatory bowel disease, and examines the methodologies used to develop them.
Read more >>
JAN
22
The fate of dietary protein in the gastrointestinal tract and implications for colonic disease
By:
Rachel H. Davis
on
JAN
22
Nature Reviews Gastroenterology & Hepatology, Published online: 22 January 2026; doi:10.1038/s41575-026-01173-0Protein is an essential nutrient in the human diet. This Review explores the fate of dietary protein in the gastrointestinal tract and its influence on colonic health and disease, providing insights into dietary protein metabolism, digestion, absorption, fermentation and the implications for colonic health.
Read more >>
JAN
09
Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms
By:
Eileen M. O’Reilly
on
JAN
09
Nature Reviews Gastroenterology & Hepatology, Published online: 09 January 2026; doi:10.1038/s41575-025-01170-9Some of the highlights in the pancreatic cancer field in 2025 include long-term data on personalized neoantigen vaccine approaches in resected pancreatic adenocarcinoma, detailed clinico-genomic analyses of large clinical trial datasets, and therapeutic strategies for early-stage disease.
Read more >>
JAN
09
Drug approvals in 2025 in gastroenterology and hepatology
By:
Eleni Kotsiliti
on
JAN
09
Nature Reviews Gastroenterology & Hepatology, Published online: 09 January 2026; doi:10.1038/s41575-026-01172-1Drug approvals in 2025 in gastroenterology and hepatology
Read more >>
JAN
09
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease
By:
Yoshio Yamauchi
on
JAN
09
Nature Reviews Gastroenterology & Hepatology, Published online: 09 January 2026; doi:10.1038/s41575-025-01168-3In this Review, Brown and colleagues describe the latest insights into the role of cholesterol synthesis and metabolism in the gut and liver, and implications in diseases such as metabolic dysfunction-associated steatotic liver disease, hepatocellular carcinoma and colorectal cancer.
Read more >>
JAN
08
Preventive hepatology for MASLD in the MENA region: reframing care from late-stage treatment to early intervention
By:
Mohamed El-Kassas
on
JAN
08
Nature Reviews Gastroenterology & Hepatology, Published online: 08 January 2026; doi:10.1038/s41575-025-01167-4Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease worldwide, with the Middle East and North Africa (MENA) being severely affected. By shifting towards preventive hepatology, MENA can mitigate the rising tide of MASLD and its complications, reduce health system costs and improve patient outcomes.
Read more >>
JAN
05
Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
By:
S. K. Sarin
on
JAN
05
Nature Reviews Gastroenterology & Hepatology, Published online: 05 January 2026; doi:10.1038/s41575-025-01159-4Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute hepatic decompensation superimposed on pre-existing chronic liver disease or cirrhosis. This Review provides an update on definitions, pathophysiological mechanisms, clinical presentation and management of ACLF.
Read more >>
Weitere Beiträge
Nephrology
Neurology
Rheumatology
Urology
JAN
28
Sperm DNA fragmentation and its influence on mammalian reproduction
By:
Mehran Dabiri
on
JAN
28
Nature Reviews Urology, Published online: 28 January 2026; doi:10.1038/s41585-025-01123-6In this Review, the authors synthesize current understanding of sperm DNA fragmentation and its effects on mammalian reproduction. Reproductive consequences for fertilization, embryo development, and pregnancy outcomes and strategies aimed at reducing or preventing DNA fragmentation are examined.
Read more >>
JAN
26
Long-term adverse effects of modern Wilms tumour therapies: implications for monitoring
By:
Filippo Spreafico
on
JAN
26
Nature Reviews Urology, Published online: 26 January 2026; doi:10.1038/s41585-026-01126-xIn this Review, the authors examine anticipated patterns of late morbidities that could emerge as a result of current treatments for Wilms tumour. Given the importance of a patient-centred follow-up strategy, they propose a practical classification system based on the likelihood of developing therapy-related late sequelae.
Read more >>
JAN
22
ctDNA-guided treatment decisions in muscle-invasive bladder cancer
By:
Lars Dyrskjøt
on
JAN
22
Nature Reviews Urology, Published online: 22 January 2026; doi:10.1038/s41585-026-01125-yThe phase III IMvigor011 trial shows that postoperative circulating tumour DNA (ctDNA) can guide adjuvant immunotherapy after cystectomy, improving outcomes in patients with ctDNA-positive tumours while identifying patients with excellent prognosis without treatment. In an era of intensified perioperative therapy, these findings might shift the focus from whom to treat towards when treatment can be safely withheld or stopped.
Read more >>
JAN
16
Circulating tumour cells as a window into lethality in prostate cancer
By:
Sophia M. Abusamra
on
JAN
16
Nature Reviews Urology, Published online: 16 January 2026; doi:10.1038/s41585-025-01121-8Circulating tumour cells (CTCs) offer a minimally invasive biopsy strategy for prostate cancer monitoring. This Review discusses the use of CTCs at all stages of prostate cancer development and treatment, from CTC isolation and enrichment strategies to the prognostic and clinical utility of these cells in prostate cancer.
Read more >>
JAN
14
A multi-modal approach for decision making in bladder cancer
By:
Hasan Al-Sattar
on
JAN
14
Nature Reviews Urology, Published online: 14 January 2026; doi:10.1038/s41585-025-01122-7In this Review, the authors describe and discuss how advances in artificial intelligence, genomics, radiomics and cytology can be integrated into decision-making processes to improve the management of bladder cancer.
Read more >>
JAN
07
Applications of AI in urology
By:
on
JAN
07
Nature Reviews Urology, Published online: 07 January 2026; doi:10.1038/s41585-025-01120-9Artificial intelligence (AI) could transform the field of urology from student education through clinical procedures to writing and reporting. In this Focus issue on the applications of AI in urology, we present articles covering a broad range of the potential uses in the field.
Read more >>
JAN
07
SRD5A2 and emerging therapies in androgen-driven disorders
By:
Zongwei Wang
on
JAN
07
Nature Reviews Urology, Published online: 07 January 2026; doi:10.1038/s41585-025-01112-9SRD5A2 has clinical relevance in benign prostatic hyperplasia, prostate cancer and other androgen-mediated conditions. In this Review, the authors describe the complementary roles of α-blockers for rapid symptom relief and 5α-reductase inhibitors for disease modification and progression risk reduction in benign prostatic hyperplasia and the potential of targeting SRD5A2 in other androgen-driven disorders.
Read more >>
JAN
06
Rethinking sexual pleasure in research, health care and society
By:
Marieke Dewitte
on
JAN
06
Nature Reviews Urology, Published online: 06 January 2026; doi:10.1038/s41585-025-01113-8Sexual pleasure has often been overshadowed by a focus on dysfunction and reproduction in sexual medicine, particularly in urology. In this Review, the authors discuss the need for multidisciplinary approaches to address the diverse experiences and needs of individuals across their lifespan, and how integrating pleasure into research, clinical practice, sexuality education and public health initiatives could enhance well-being, intimate relationships and overall quality of life.
Read more >>
Weitere Beiträge
Share
Tweet
Share
Mail
English version of this site is mostly translated automatically using "google translate". In case of language difficulties please do not hesitate to contact me.
Share by: